TheProfitWatch

CVKD - Cadrenal Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
11.25 -1.08 (-9.6%) --- --- -0.31 (-2.96%) --- -1.08 (-9.6%) --- ---

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
-1.87
Diluted EPS:
-1.87
Basic P/E:
-5.4385
Diluted P/E:
-5.4385
RSI(14) 1m:
44.38
VWAP:
10.18
RVol:

Events

Period Kind Movement Occurred At

Related News